Navigation Links
Conatus Pharmaceuticals Inc. Files Registration Statement for Proposed Initial Public Offering
Date:6/14/2013

SAN DIEGO, June 14, 2013 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not been determined. All shares of the common stock to be sold in the offering will be offered by Conatus.

Stifel and Piper Jaffray & Co. are acting as joint book-running managers for the offering. JMP Securities LLC is acting as co-lead manager and SunTrust Robinson Humphrey, Inc. is acting as co-manager for the offering. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by calling (415) 364-2720 or by emailing SyndicateOps@stifel.com, and from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by calling (800) 747-3924 or by emailing prospectus@pjc.com.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful,
'/>"/>

SOURCE Conatus Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Conatus Pharmaceuticals Appoints Daniel Ripley As Head Of Corporate Development
2. Arena Pharmaceuticals to Present at the 2013 Wells Fargo Securities Healthcare Conference
3. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
4. Omthera Pharmaceuticals Announces Record Date and Meeting Date for Special Meeting of Stockholders
5. Chronic Kidney Disease: Reducing Risks of Progression-- Prismic Pharmaceuticals Secures Exclusive Licensing Rights
6. Anthera Pharmaceuticals Announces Personnel Changes
7. Zydus Pharmaceuticals USA Inc. Issues Voluntary Nationwide Recall of Warfarin 2 mg Tablets, Lot MM5767, Expiration Date June 2014, Due to Oversized Tablets
8. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
9. Access Pharmaceuticals Signs US License Agreement With AMAG Pharmaceuticals For MuGard
10. HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase 2b Clinical Study of HQK-1001 in Patients with Sickle Cell Disease
11. Oramed Pharmaceuticals to Present at IATI-BioMed Conference in Israel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... HARBIN, China, Oct. 25, 2011 /PRNewswire-Asia/ -- China Botanic ... Botanic" or the "Company"), a developer, manufacturer and distributor ... in China, today announced that the Company has recently ... in the field of Traditional Chinese Medicine (TCM) and ...
... 25, 2011 Merz Pharmaceuticals, LLC, today announced that ... profiles of Xeomin® (incobotulinumtoxinA), a botulinum toxin type A ... (eyelid spasms) will be presented at the 115th Annual ... Orlando, Fla. These data include an extension ...
Cached Medicine Technology:China Botanic Hosts Technical Exchange for Industry Research Experts 2China Botanic Hosts Technical Exchange for Industry Research Experts 3Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 2Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 3Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 4Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 5Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 6Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 7Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 8
(Date:4/24/2014)... corresponding terminology, and the relevance of palliation in ... on randomized controlled trials (RCTs). This is the ... for Quality and Efficiency in Health Care (IQWiG), ... , Together with external experts, IQWiG analysed studies ... cancer, malignant melanoma, and pancreatic cancer. For this ...
(Date:4/24/2014)... Dartmouth has been awarded one of 30 grants ... a Lead Academic Participating Site in its new ... are a select groups of investigators charged with distributing ... groups., The NCTN grant system reflects recommendations from a ... operations to achieve four goals:, Faster design, ...
(Date:4/23/2014)... Massachusetts General Hospital (MGH) investigators may lead to greater ... serious medical problem use of fecal material from ... Clostridium difficile ( C. difficile ) bacteria. ... journal Clinical Infectious Diseases , the researchers report ... unrelated to patients was as successful in curing recurrent ...
(Date:4/23/2014)... John J. O,Shea, M.D., scientific director at the National ... has been named the 2014 recipient of the Ross ... peer-reviewed, open-access journal Molecular Medicine . The award ... York Academy of Sciences in Manhattan, followed by scientific ... is part of the National Institutes of Health. , ...
(Date:4/23/2014)... Purdue University researchers have identified an important enzyme pathway ... or too few chromosomes, a condition that has been ... Hall, associate professor of biochemistry, found that near the ... an enzyme that ensures any breaks in DNA are ... the genome to daughter cells. This process helps safeguard ...
Breaking Medicine News(10 mins):Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... Texas, Feb. 12 Benjamin M. Cutler, ... Inc. (USHEALTH), a leading,national health insurer providing ... self-employed, announced today the promotion of Konrad ... Officer. In this,expanded role, Kober will oversee ...
... 7 Million Shares Shorted Since March 2006 According to ... ... BioElectronics,Corporation (Pink Sheets: BIEL) announced today that BUYINS.NET, http://www.buyins.net, ... sale data to February 2008. From March 2006 to,February 2008 ...
... a set of cues that we then use to make ... service or more expensive candles smell better. However, this set ... learn and recognize other real, positive qualities that are indicated ... April issue of the Journal of Consumer Research. , ...
... celebrities and,socialites have flocked to France for their ... and urban dwellers alike have,to go no further ... oral,care., (Photo: http://www.newscom.com/cgi-bin/prnh/20080212/LATU026 ), Elgydium(R), ... three,decades, has been available in the U.S. on ...
... Su Salud. Su Voz., Campaign to Address Lack of Public Awareness ... to File Medicare Quality of Care Complaints, ... join leaders of health care organizations and senior,groups, along with public ... Salud. Su Voz. Partnership to educate Latino,seniors about their right to ...
... DENVER, Feb. 12 PSI, a leading provider ... today the,signing of a contract with the Ohio ... delivering new hire reporting services for the State ... The new contract will run,for an initial period ...
Cached Medicine News:Health News:USHEALTH Group Announces Appointment of Executive Vice President 2Health News:BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11 2Health News:BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11 3Health News:BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11 4Health News:BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11 5Health News:BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11 6Health News:Old dogs: Prior knowledge affects how consumers accept new information 2Health News:A Favorite in France, Elgydium(R) Toothpaste Makes Entrance Into the U.S. Market 2Health News:Milly Quezada, 'Queen of Merengue,' to Launch Partnership to Educate Latino Seniors About Health Care Rights 2Health News:Milly Quezada, 'Queen of Merengue,' to Launch Partnership to Educate Latino Seniors About Health Care Rights 3Health News:Ohio Selects Policy Studies Inc. (PSI) to Continue Operating Its New Hire Reporting Program 2
... Multi frequency and multigate ... detection and fitted with ... tests for hemodynamic evaluation. ... as well for routine ...
The Spencer Technologies PMD 100 (TCD 100M) is the worlds first stand-alone digital transcranial doppler system....
Swiss Watchmaker Forceps, 4" extra-long precision ground points....
The vertebral body replacement (VBR) is used for the anterior thoracic and lumbar spine. It is intended for use in the thoracic and lumbar spine to replace a collapsed, damaged, or unstable vertebral...
Medicine Products: